Stockscreener 앱 받기
144.58
1.52%
-2.2705
전일 마감가:
$146.85
열려 있는:
$146.01
하루 거래량:
538.99K
Relative Volume:
0.60
시가총액:
$14.34B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
49.01
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-6.58%
1개월 성능:
+5.29%
6개월 성능:
+23.74%
1년 성능:
+15.23%
1일 변동 폭
$144.17
$148.84
1주일 범위
$144.17
$154.50
52주 변동 폭
$84.23
$157.67
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
144.54 | 14.64B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
121.25 | 53.43B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.22 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.915 | 44.00B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
25.61 | 29.63B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
466.43 | 19.87B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
How to build a dashboard for Neurocrine Biosciences Inc. stockWeekly Market Summary & Expert Approved Momentum Ideas - newser.com
Can Neurocrine Biosciences Inc. stock weather global recession2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance
Measuring Neurocrine Biosciences Inc.’s beta against major indices2025 Winners & Losers & Weekly Return Optimization Alerts - newser.com
What analysts say about Neurocrine Biosciences Inc stockPrice Volatility Patterns & Small Budget Growth - earlytimes.in
Neurocrine Biosciences to Present at Upcoming Investor Conferences - Your Wyoming Link
Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News - Yahoo Finance
What analysts say about Neurocrine Biosciences Inc NB3 stockSector Performance Review & Free Turn Volatility To Profit - earlytimes.in
Neurocrine’s depression candidate fails mid-stage study but analysis continues - The Pharma Letter
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherWeekly Gains Report & Daily Profit Focused Screening - newser.com
Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal - simplywall.st
Is it time to cut losses on Neurocrine Biosciences Inc.Portfolio Update Report & Real-Time Chart Pattern Alerts - newser.com
What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investorsGlobal Markets & Entry Point Confirmation Signals - newser.com
What valuation multiples suggest for Neurocrine Biosciences Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Neurocrine Biosciences fails mid-stage study of depression drug - MSN
Why Neurocrine Biosciences Inc. stock remains resilientProduct Launch & High Return Trade Opportunity Guides - newser.com
Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression - MedCity News
Neurocrine (Nasdaq: NBIX) to join Jefferies Nov. 18, Piper Sandler Dec. 2 webcasts - Stock Titan
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com
How Neurocrine Biosciences Inc. stock responds to policy changesWeekly Trend Recap & Verified Short-Term Trading Plans - newser.com
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
Neurocrine’s Depression Drug Misses In Phase II - Citeline News & Insights
Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 - Investing.com Nigeria
Neurocrine’s depression drug fails to meet primary endpoint in phase 2 By Investing.com - Investing.com South Africa
Neurocrine chalks up a depression drug failure - BioPharma Dive
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Is Neurocrine Biosciences Inc. stock trading near support levelsStop Loss & Growth Focused Stock Pick Reports - newser.com
What moving averages say about Neurocrine Biosciences Inc.2025 Bull vs Bear & Smart Allocation Stock Reports - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Risk Management & Free Community Consensus Stock Picks - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock split increase liquidity2025 Price Action Summary & Detailed Earnings Play Alerts - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Macro Moves & Long-Term Growth Portfolio Plans - newser.com
What data driven models say about Neurocrine Biosciences Inc.’s future2025 Retail Activity & Free Weekly Chart Analysis and Trade Guides - newser.com
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Action & Precise Swing Trade Entry Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsJuly 2025 Market Mood & Real-Time Stock Movement Alerts - newser.com
Neurocrine Biosciences (NBIX) Is Up 12.1% After Strong Q3 Earnings Report and Upgraded Guidance – Has The Bull Case Changed? - Sahm
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RASTETTER WILLIAM H | Director |
Nov 05 '25 |
Sale |
151.82 |
18,000 |
2,732,690 |
40,360 |
0.23%
0.11%
자본화:
|
볼륨(24시간):